← Back to Clinical Trials
Recruiting NCT07894796

NCT07894796 A Study to Assess the Efficacy of a Calcium Sodium Phosphosilicate Toothpaste for the Relief of Dentine Hypersensitivity

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07894796
Status Recruiting
Phase —
Sponsor HALEON
Condition Dentin Sensitivity
Study Type INTERVENTIONAL
Enrollment 192 participants
Start Date 2026-10-19
Primary Completion 2027-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Test ToothpasteRegular Fluoride Toothpaste

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 192 participants in total. It began in 2026-10-19 with a primary completion date of 2027-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to demonstrate the clinical efficacy of the Test Toothpaste containing Calcium Sodium Phosphosilicate (CSPS) in reducing Dentin Hypersensitivity (DH) to an evaporative (air) stimulus, compared to a sodium fluoride Reference Toothpaste, after 8 Weeks of twice daily use.

Eligibility Criteria

Inclusion Criteria: * Participant provision of signed and dated informed consent before any study procedures are performed. * Participant is willing and able to comply with the study visit schedule, product usage instructions, lifestyle restrictions, and other study procedures. * Participant is in good general, oral and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in self-reported medical history, or upon oral examination, that would impact their safety or wellbeing, or the outcomes of the study, if they were to participate in the study, or affect their ability to understand and follow study requirements. Screening (Visit 1): Participant must have 1. History of tooth sensitivity lasting more than six months but not more than 10 years (self-reported). 2. Good general oral health, with a minimum of 20 natural teeth. 3. Minimum of 2 accessible, non-adjacent teeth (incisors, canines, premolars), in different quadrants, which meet all the following criteria: 1. Exposed dentine due to facial/cervical erosion, abrasion, or gingival recession (EAR). 2. Modified Gingival Index (MGI)= 0 directly adjacent to the exposed dentine \[that is (i.e.), the test area only\]. 3. Clinical mobility= 0. 4. Clinically confirmed DH to both tactile and evaporative (air) stimuli: Qualifying tactile threshold less than or equal to (\<=) 20g and Qualifying Schiff sensitivity score more than or equal to (\>=) 2. Baseline (Visit 2, Pre-Treatment) * Participant must have a minimum of two non-adjacent, accessible teeth (incisors, canines, premolars), in different quadrants, with clinically confirmed DH to both tactile and evaporative (air) stimuli at both Screening (Visit 1) and Baseline (Visit 2). 1. Qualifying Tactile threshold \<= 20g at Screening and Baseline. 2. Qualifying Schiff sensitivity score \>= 2 at Screening and Baseline. * The clinical examiner will select two 'test teeth' from those which meet the tactile threshold and Schiff sensitivity score inclusion criteria at both Screening and Baseline. Exclusion Criteria: * Participant is an employee of the investigator site directly involved in the conduct of the study, or an employee of the investigator site otherwise supervised by the investigator, or a member of their immediate family. * Participant is an employee of the sponsor directly involved in the conduct of the study or a member of their immediate family. * Female participant who is pregnant or intending to become pregnant during the study (self-reported). * Female participant who is breastfeeding (self-reported). * Participant with known or suspected intolerance or hypersensitivity to the study products, any of their stated ingredients or closely related compounds (self-reported). * Participant with a recent history (within the last year) of alcohol or other substance abuse (self-reported). * Participant is participating in or has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days of Screening (Visit 1) or plans to participate in other studies (including non-medicinal studies) during this study. * Participant has participated in a tooth sensitivity study within 8 weeks of Screening (Visit 1), or participated in Haleon-sponsored study number 300100. * Participant is currently using an oral care product indicated for DH relief or care of sensitive teeth or has used such a product within 8 weeks of Screening (Visit 1). * Participant takes daily doses of medications/treatments which, in the opinion of the investigator or medically qualified designee, could interfere with their perception of tooth sensitivity \[for example (e.g.), analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilizers, antidepressants, mood-altering and anti-inflammatory drugs\]. * Participant has taken antibiotics in the 2 weeks prior to Screening (Visit 1). * Participant has taken antibiotics in the 2 weeks prior to Baseline (Visit 2), i.e., during the acclimatization period. * Participant takes daily doses of a medication which, in the opinion of the investigator or medically qualified designee, is causing xerostomia. * Participant requires antibiotic prophylaxis for dental procedures. * Participant has had professional tooth de-sensitizing treatment within 8 weeks of Screening (Visit 1). * Participant has had a tooth bleaching procedure within 8 weeks of Screening (Visit 1). * Participant has had dental prophylaxis or supragingival Professional Mechanical Plaque Removal (PMPR) within 4 weeks of Screening (Visit 1). * Participant has had treatment for periodontal disease (including surgery) within 12 months of Screening (Visit 1). * Participant has had subgingival instrumentation within 3 months of Screening (Visit 1). * Participant with gross periodontal disease. * Participant with a tongue or lip piercing in the area of the test teeth. * Participant with evidence of gross intra-oral neglect or the need for extensive dental therapy. * Participant with a fixed or removable partial prosthesis which, in the opinion of the investigator or dentally qualified designee, could impact study outcomes. * Participant with multiple dental implants which, in the opinion of the investigator or dentally qualified designee, could impact study outcomes. * Participant has had orthodontic treatment (fixed or removable orthodontic braces/bands) within 6 months of Screening (Visit1). * Participant with a fixed or removable orthodontic retainer which, in the opinion of the investigator or dentally qualified designee, could impact study outcomes (e.g., Participant who is an intermittent user of a removable orthodontic retainer). Note: Teeth involved in a fixed orthodontic retainer may be used as 'test teeth' if, in the opinion of the investigator or dentally qualified designee, their selection would not impact study outcomes. * Specific Dentition Exclusions for 'Test teeth': 1. Tooth with evidence of current/recent caries. 2. Tooth with (self-reported) treatment for decay within 12 months of Screening (Visit 1). 3. Tooth with exposed dentine and deep, defective, or facial restorations. 4. Tooth with a full crown or veneer. 5. Tooth adjacent to a bridge abutment or crown which, in the opinion of the investigator or dentally qualified designee, could impact study outcomes. 6. Sensitive tooth with contributing etiologies other than EAR to exposed dentine. 7. Sensitive tooth not expected to benefit from use of an anti-sensitivity toothpaste, in the opinion of the investigator or dentally qualified designee. * Participant has previously been enrolled in this study. * Participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.

Contact & Investigator

Central Contact

Haleon Response Center

✉ ww.clinical-trial-register@haleon.com

📞 +441932 95 95 00

Principal Investigator

C. R. Goyal

PRINCIPAL INVESTIGATOR

All Sum Research Center Ltd.

Frequently Asked Questions

Who can join the NCT07894796 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Dentin Sensitivity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07894796 currently recruiting?

Yes, NCT07894796 is actively recruiting participants. Contact the research team at ww.clinical-trial-register@haleon.com for enrollment information.

Where is the NCT07894796 trial being conducted?

This trial is being conducted at Mississauga, Canada.

Who is sponsoring the NCT07894796 clinical trial?

NCT07894796 is sponsored by HALEON. The principal investigator is C. R. Goyal at All Sum Research Center Ltd.. The trial plans to enroll 192 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology